Resistance to a long-acting somatostatin analog (SMS 201-995) reversed by surgery in acromegaly

J Endocrinol Invest. 1990 Sep;13(8):683-7. doi: 10.1007/BF03349598.

Abstract

A 42-year-old woman had acromegaly and a large macroadenoma with supra- and parasellar extension. Her GH levels (median 85 ng/ml, range 63-170 ng/ml) were not responsive to TRH (200 micrograms iv), GHRH (100 micrograms iv) and bromocriptine (Br 2.5 mg po) acute tests; Sm-C level was 8 U/ml. She was treated with octreotide (SMS) (up to 1500 micrograms daily) for 3 months. No changes of clinical, biochemical and radiological findings were seen, therefore she underwent transsphenoidal surgery. After surgery, hypopituitarism and diabetes insipidus appeared: GH levels remained high (median 45 ng/ml; range 37-56 ng/ml), but became responsive to Br acute test. The patient was given SMS again, and this resulted in clinical improvement, marked reduction of GH and Sm-C levels and slight shrinkage of the residual tumor. Speculative hypotheses about this previously unreported phenomenon might be either an excess of both GHRH and somatostatin, caused by a primary increase of dopaminergic tone, or a primary excess only of GHRH; in both cases the surgical lesion of the hypothalamic-pituitary region might have impaired the neurohormones inflow to the residual pituitary and so let SMS and Br exert their inhibitory actions on GH secretion.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acromegaly / drug therapy
  • Acromegaly / surgery
  • Acromegaly / therapy*
  • Adenoma / complications
  • Adenoma / surgery
  • Adult
  • Drug Resistance
  • Female
  • Growth Hormone / blood
  • Humans
  • Octreotide / therapeutic use*
  • Pituitary Neoplasms / complications
  • Pituitary Neoplasms / surgery
  • Prolactin / blood
  • Radioimmunoassay
  • Tomography, X-Ray Computed

Substances

  • Prolactin
  • Growth Hormone
  • Octreotide